Affordable Access

deepdyve-link
Publisher Website

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

Authors
  • Fanale, Michelle A1
  • Horwitz, Steven M2
  • Forero-Torres, Andres3
  • Bartlett, Nancy L4
  • Advani, Ranjana H5
  • Pro, Barbara6
  • Chen, Robert W7
  • Davies, Andrew8
  • Illidge, Tim9
  • Uttarwar, Mayur10
  • Lee, Shih-Yuan11
  • Ren, Hong10
  • Kennedy, Dana A10
  • Shustov, Andrei R12
  • 1 University of Texas MD Anderson Cancer Center, Houston, TX.
  • 2 Memorial Sloan-Kettering Cancer Center, New York, NY.
  • 3 Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL.
  • 4 Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO.
  • 5 Stanford University Medical Center, Palo Alto, CA.
  • 6 Fox Chase Cancer Center, Philadelphia, PA.
  • 7 City of Hope National Medical Center, Duarte, CA.
  • 8 Cancer Research UK Centre, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. , (United Kingdom)
  • 9 Christie Hospital NHS, Manchester, United Kingdom. , (United Kingdom)
  • 10 Seattle Genetics, Inc., Bothell, WA.
  • 11 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Limited, Cambridge, MA; and.
  • 12 University of Washington Medical Center, Seattle, WA.
Type
Published Article
Journal
Blood
Publisher
American Society of Hematology
Publication Date
May 10, 2018
Volume
131
Issue
19
Pages
2120–2124
Identifiers
DOI: 10.1182/blood-2017-12-821009
PMID: 29507077
Source
Medline
Language
English
License
Unknown

Abstract

This phase 1 study evaluated frontline brentuximab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy) in 26 patients with CD30+ peripheral T-cell lymphoma, including 19 with systemic anaplastic large cell lymphoma. All patients (100%) achieved an objective response, with a complete remission (CR) rate of 92%; none received a consolidative stem cell transplant. After a median observation period of 59.6 months (range, 4.6-66.0) from first dose, neither the median progression-free survival (PFS) nor the median overall survival (OS) was reached. No progression or death was observed beyond 35 months. The estimated 5-year PFS and OS rates were 52% and 80%, respectively. Eighteen of 19 patients (95%) with treatment-emergent peripheral neuropathy (PN) reported resolution or improvement of symptoms. Thirteen patients (50%) remained in remission at the end of the study, with PFS ranging from 37.8+ to 66.0+ months. Eight of these 13 patients received the maximum 16 cycles of study treatment. These final results demonstrate durable remissions in 50% of patients treated with frontline BV+CHP, suggesting a potentially curative treatment option for some patients. This trial was registered at www.clinicaltrials.gov as #NCT01309789. © 2018 by The American Society of Hematology.

Report this publication

Statistics

Seen <100 times